Gliptins may cause severe joint pain
The FDA has issued a safety announcement warning the DPP-4 inhibitors or gliptins may cause joint pain that can be "severe and disabling".
A review of adverse events reported to the FDA and also medical literature identified cases of severe joint pain associated with the use of DPP-4 inhibitors. The pain may begin soon after starting treatment or after several years.
Arthralgia is listed as a known side effect in the current SPCs for sitagliptin, saxagliptin and vildagliptin. However, alogliptin and linagliptin are also mentioned in the FDA announcement.
Patients are advised to report severe and persistent joint pain to a healthcare professional. If appropriate the healthcare professional should consider stopping treatment; symptoms usually improve within a month.
Action: Clinicians should be aware of this apparent side effect and take appropriate action when it is encountered.
| « Drug Safety Update - September 2015 | NICE Guidance - September 2015 » |
Leave a Comment